Arcus Biosciences, Inc. announced a private placement of 15,238,096 common shares at a price of $21 per share for the gross proceeds of $320,000,016 on January 29, 2024. The transaction will include participation from returning investor Gilead Sciences, Inc. for 33% stake.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.55 USD | +5.57% | +6.58% | -18.59% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
65.42 USD | +0.23% | -2.01% | 81.58B | ||
15.55 USD | +5.57% | +6.58% | 1.41B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.59% | 1.41B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Arcus Biosciences, Inc. announced that it expects to receive $320.000016 million in funding from Gilead Sciences, Inc.